More recently, gevokizumab, a recombinant humanized monoclonal antibody that neutralizes IL-1β and preserves IL-1α signaling, has been tested for its therapeutic impact in subjects with T2DM [88]. This evidence concerns the gene IL1B and type 2 diabetes mellitus.